| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TEVA | Ordinary Shares | Options Exercise | +24.9K | 24.9K | Mar 3, 2024 | Direct | F1, F2 | |||
| transaction | TEVA | Ordinary Shares | Sale | -$107K | -8.05K | -32.31% | $13.34 | 16.9K | Mar 4, 2024 | Direct | F1, F3, F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TEVA | Restricted Share Units | Options Exercise | $0 | -24.9K | -25% | $0.00 | 74.7K | Mar 3, 2024 | Ordinary Shares | 24.9K | Direct | F1, F2, F6 | |
| transaction | TEVA | Restricted Share Units | Award | $0 | +93K | $0.00 | 93K | Mar 4, 2024 | Ordinary Shares | 93K | Direct | F1, F2, F7 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| F2 | Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| F3 | The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. |
| F4 | Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F6 | Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. |
| F7 | Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028. |
Executive Vice President, Global R&D and Chief Medical Officer